FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954830972> ?p ?o ?g. }

• W2954830972 endingPage "2927" @default.
• W2954830972 startingPage "2927" @default.
• W2954830972 abstract "Abstract Radiation therapy is a standard type of treatment modality used to achieve local control in more than 50% of all cancer patients. However, tumor hypoxia reduces the effectiveness of radiation therapy by limiting the biologically effective dose. Limited distribution of oxygen is a direct consequence of abnormalities in vascular structure and angiogenesis that fails to provide sufficient oxygen to meet the demands of metabolically hyperactive cancer cells. An acute increase in tumor oxygenation prior to radiation treatment should therefore significantly improve the tumor cell kill after radiation. Nonetheless, therapeutic efforts to increase oxygen delivery to the tumor have not shown positive clinical results to this day. We have taken an alternative route by targeting the demand for oxygen rather than its supply. In the cell, mitochondrial respiration is the major oxygen-consuming process. We show that pharmacological inhibition of mitochondrial oxygen consumption (OCR) temporarily reduces the tumor cells’ demand for oxygen leading to increased tumor oxygenation and enhanced radiation response. We identified a previously unrecognized activity of the FDA-approved drug papaverine as an inhibitor of mitochondrial complex I. In vivo, a single clinically achievable dose of papaverine increased tumor, but not normal tissue oxygenation within 45 minutes and strikingly enhanced tumor response to radiation therapy in both ortho- and heterotopic rodent tumor models. Moreover, our GI tract studies show that this can be achieved without exacerbating normal tissue toxicity, as papaverine does not radiosensitize hypoxic normal tissues. Papaverine is an ergot alkaloid originally isolated from Papaver somniferum in 1848. It was used for decades as smooth muscle relaxant to treat vasospasms and erectile dysfunction. Its vascular effects were believed to be mediated by its ability to inhibit phosphodiesterase 10A (PDE10A). We provide genetic evidence that papaverine’s complex I inhibition, not its activity as a PDE10A inhibitor is directly responsible for increased oxygenation and enhanced radiation response. Furthermore, we describe novel derivatives of papaverine that have the potential to become a new generation of clinical radiosensitizers with potentially fewer side effects. Papaverine has a short half-life of 90-120 minutes, is cell-permeable, reversible and quickly cleared from the patient. In vitro, all 28 cancer and normal cell lines tested were sensitive to papaverine regardless of their oncogenic landscape, suggesting possible application for a broad spectrum of cancers that depends primarily on their level of hypoxia. In conclusion, PPV or one of its novel derivatives appear to be ideal candidates for clinical radiosensitization, applicable primarily in cancers where local control increases the overall survival. Citation Format: Martin Benej, Xiangqian Hong, Sandip Vibhute, Sabina Scott, Jinghai Wu, Edward Graves, Quynh-Thu Le, Albert C. Koong, Amato J. Giaccia, Ching-Shih Chen, Bing Yu, Ioanna Papandreou, Nicholas C. Denko. Papaverine and its novel derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2927." @default.
• W2954830972 created "2019-07-12" @default.
• W2954830972 creator A5004527351 @default.
• W2954830972 creator A5013860869 @default.
• W2954830972 creator A5029060159 @default.
• W2954830972 creator A5039195747 @default.
• W2954830972 creator A5040477864 @default.
• W2954830972 creator A5056252373 @default.
• W2954830972 creator A5056692526 @default.
• W2954830972 creator A5069659054 @default.
• W2954830972 creator A5070648746 @default.
• W2954830972 creator A5071185138 @default.
• W2954830972 creator A5080172191 @default.
• W2954830972 creator A5085857963 @default.
• W2954830972 creator A5090516617 @default.
• W2954830972 date "2019-07-01" @default.
• W2954830972 modified "2023-09-27" @default.
• W2954830972 title "Abstract 2927: Papaverine and its novel derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism" @default.
• W2954830972 doi "https://doi.org/10.1158/1538-7445.am2019-2927" @default.
• W2954830972 hasPublicationYear "2019" @default.
• W2954830972 type Work @default.
• W2954830972 sameAs 2954830972 @default.
• W2954830972 citedByCount "0" @default.
• W2954830972 crossrefType "journal-article" @default.
• W2954830972 hasAuthorship W2954830972A5004527351 @default.
• W2954830972 hasAuthorship W2954830972A5013860869 @default.
• W2954830972 hasAuthorship W2954830972A5029060159 @default.
• W2954830972 hasAuthorship W2954830972A5039195747 @default.
• W2954830972 hasAuthorship W2954830972A5040477864 @default.
• W2954830972 hasAuthorship W2954830972A5056252373 @default.
• W2954830972 hasAuthorship W2954830972A5056692526 @default.
• W2954830972 hasAuthorship W2954830972A5069659054 @default.
• W2954830972 hasAuthorship W2954830972A5070648746 @default.
• W2954830972 hasAuthorship W2954830972A5071185138 @default.
• W2954830972 hasAuthorship W2954830972A5080172191 @default.
• W2954830972 hasAuthorship W2954830972A5085857963 @default.
• W2954830972 hasAuthorship W2954830972A5090516617 @default.
• W2954830972 hasBestOaLocation W29548309721 @default.
• W2954830972 hasConcept C121608353 @default.
• W2954830972 hasConcept C126322002 @default.
• W2954830972 hasConcept C150903083 @default.
• W2954830972 hasConcept C207001950 @default.
• W2954830972 hasConcept C2776952824 @default.
• W2954830972 hasConcept C2780394083 @default.
• W2954830972 hasConcept C28859421 @default.
• W2954830972 hasConcept C42219234 @default.
• W2954830972 hasConcept C502942594 @default.
• W2954830972 hasConcept C509974204 @default.
• W2954830972 hasConcept C55493867 @default.
• W2954830972 hasConcept C70289976 @default.
• W2954830972 hasConcept C71924100 @default.
• W2954830972 hasConcept C86803240 @default.
• W2954830972 hasConcept C96232424 @default.
• W2954830972 hasConcept C98274493 @default.
• W2954830972 hasConceptScore W2954830972C121608353 @default.
• W2954830972 hasConceptScore W2954830972C126322002 @default.
• W2954830972 hasConceptScore W2954830972C150903083 @default.
• W2954830972 hasConceptScore W2954830972C207001950 @default.
• W2954830972 hasConceptScore W2954830972C2776952824 @default.
• W2954830972 hasConceptScore W2954830972C2780394083 @default.
• W2954830972 hasConceptScore W2954830972C28859421 @default.
• W2954830972 hasConceptScore W2954830972C42219234 @default.
• W2954830972 hasConceptScore W2954830972C502942594 @default.
• W2954830972 hasConceptScore W2954830972C509974204 @default.
• W2954830972 hasConceptScore W2954830972C55493867 @default.
• W2954830972 hasConceptScore W2954830972C70289976 @default.
• W2954830972 hasConceptScore W2954830972C71924100 @default.
• W2954830972 hasConceptScore W2954830972C86803240 @default.
• W2954830972 hasConceptScore W2954830972C96232424 @default.
• W2954830972 hasConceptScore W2954830972C98274493 @default.
• W2954830972 hasIssue "13_Supplement" @default.
• W2954830972 hasLocation W29548309721 @default.
• W2954830972 hasOpenAccess W2954830972 @default.
• W2954830972 hasPrimaryLocation W29548309721 @default.
• W2954830972 hasRelatedWork W1572983296 @default.
• W2954830972 hasRelatedWork W2040055558 @default.
• W2954830972 hasRelatedWork W2349030099 @default.
• W2954830972 hasRelatedWork W2359165709 @default.
• W2954830972 hasRelatedWork W2378785636 @default.
• W2954830972 hasRelatedWork W2384708512 @default.
• W2954830972 hasRelatedWork W4283771460 @default.
• W2954830972 hasRelatedWork W4304116770 @default.
• W2954830972 hasRelatedWork W568938955 @default.
• W2954830972 hasRelatedWork W70240196 @default.
• W2954830972 hasVolume "79" @default.
• W2954830972 isParatext "false" @default.
• W2954830972 isRetracted "false" @default.
• W2954830972 magId "2954830972" @default.
• W2954830972 workType "article" @default.